Milestone Pharmaceuticals Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Milestone Pharmaceuticals Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $28.00K, a 22.22% decline year-over-year.
- Milestone Pharmaceuticals Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $286.00K, a 1091.67% increase year-over-year.
- Milestone Pharmaceuticals Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $123.00K.
- Milestone Pharmaceuticals Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $36.00K, a 24.14% increase year-over-year.
- Milestone Pharmaceuticals Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $444.00K, a 737.74% increase from fiscal 2024.
- Milestone Pharmaceuticals Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $53.00K, a 71.96% decline from fiscal 2023.
- Milestone Pharmaceuticals Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $189.00K, a 55.00% decline from fiscal 2022.
- Milestone Pharmaceuticals Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $420.00K, a 247.11% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $28.00K 10-Q · filed 2026-08-12 | |
| 2025-12-31 | $286.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $444.00K 10-K · filed 2026-03-20 |
| 2025-09-30 | $123.00K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $36.00K 10-Q · filed 2026-08-12 | |
| 2024-12-31 | $24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $53.00K 10-K · filed 2026-03-20 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $147.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $29.00K 10-Q · filed 2025-08-12 | $187.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $117.00K 10-Q · filed 2025-05-14 | $182.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $189.00K 10-K · filed 2025-03-13 |
| 2023-09-30 | $40.00K 10-Q · filed 2024-11-12 | $391.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $24.00K 10-Q · filed 2024-08-08 | $379.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $124.00K 10-Q · filed 2024-05-13 | $495.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $203.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $420.00K 10-K · filed 2024-03-21 |
| 2022-09-30 | $28.00K 10-Q · filed 2023-11-13 | $295.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $140.00K 10-Q · filed 2023-08-10 | $291.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $49.00K 10-Q · filed 2023-05-11 | $151.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $78.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $121.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $24.00K 10-Q · filed 2022-11-10 | $46.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $70.00K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $19.00K 10-Q · filed 2022-05-12 | $242.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $300.00K 10-K · filed 2022-03-24 |
| 2020-09-30 | $48.00K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $172.00K 10-Q · filed 2021-08-11 | |
| 2020-03-31 | $77.00K 10-Q · filed 2021-08-11 | |
| 2019-12-31 | $44.00K 10-K · filed 2021-03-29 | |
| 2019-03-31 | $25.00K 10-Q · filed 2020-11-13 | |
| 2018-12-31 | $461.00K 10-K/A · filed 2020-10-23 | |
| 2018-06-30 | $7.00K 10-Q · filed 2019-11-13 | |
| 2018-03-31 | $30.00K 10-Q · filed 2019-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |